Provided by Tiger Trade Technology Pte. Ltd.

EVEREST MED

30.140
+2.1607.72%
Volume:9.34M
Turnover:277.40M
Market Cap:10.67B
PE:-33.87
High:30.480
Open:28.020
Low:28.020
Close:27.980
52wk High:58.600
52wk Low:22.700
Shares:354.00M
HK Float Shares:354.00M
Volume Ratio:2.31
T/O Rate:2.64%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.890
ROE:-1.18%
ROA:-1.06%
PB:1.75
PE(LYR):-33.87
PS:3.79

Loading ...

EVEREST MED Grants 473,000 Share Options and 1.3985 Million Awards

Stock News
·
Jul 17

Everest Medicines Grants 1,398,527 Share Awards Under 2026 Share Scheme

Reuters
·
Jul 17

Movement Alert|Everest Medicines Falls 7.83% in Regular Trading, Biotech Sector Selloff Drags Down Individual Stocks

Market Focus
·
Jul 17

Three Core Emergency Drugs from Everest Med Included in China's 2026 National Essential Medicines List

Deep News
·
Jul 16

Movement Alert|Everest Medicines Rises 6.67% in Regular Trading, EVER001 Licensing Deal Closure and Biotech Sector Rally Drive Gains

Market Focus
·
Jul 15

EVEREST MED seals US$1.14 billion licensing and collaboration deal with Travere Therapeutics

Bulletin Express
·
Jul 07

EVEREST MED Completes Transaction with Travere Therapeutics for Exclusive Licensing and Collaboration Agreement

Stock News
·
Jul 07

Everest Medicines Closes Exclusive Licensing, Collaboration Deal with Travere for Us$112.5 Million Upfront

Reuters
·
Jul 07

Everest Med Adds 6,900 Shares in June; Total Issued Shares Reach 353.83 Million

Bulletin Express
·
Jul 07

Movement Alert|Everest Medicines Falls 5.03% in Regular Trading, Trading at HK$27.2

Market Focus
·
Jul 07

Movement Alert|Everest Medicines Intraday Rise 7.05%, Multiple BD Catalysts Combined with Biotech Sector Momentum

Market Focus
·
Jul 06

Movement Alert|Everest Medicines Intraday Rise 8.16%, PCSK9 Inhibitor BLA Acceptance Combined with Multiple Positive Catalysts

Market Focus
·
Jul 02

From Asset Portfolio to Cash Flow Generation: The Core Rationale for Reassessing Everest MED

Deep News
·
Jun 30

Vikail Pharma’s Vicagrel Antithrombotic Drug Wins China Filing Acceptance for Market Approval

Reuters
·
Jun 30

Everest Medicines Shareholders Adopt 2025 Audited Financial Statements at AGM

Reuters
·
Jun 26

Movement Alert|Everest Medicines Falls 5.48% in Regular Trading, Nefecon Patent Settlement Sparks Continued Concerns Over Weakened Exclusivity Premium

Market Focus
·
Jun 26

Movement Alert|Everest Medicines Falls 5.15% in Regular Trading, Patent Settlement Allows First Generic of Core Drug Nefecon to Enter Market

Market Focus
·
Jun 25

Changan Huitong-backed Mico Pharma Jumps 103% in Hong Kong Debut After HKD 1.06 Billion IPO

Reuters
·
Jun 24

EVEREST MED Forges Commercial Partnership with Hainan Herui for Budesonide Enteric-Coated Capsules

Stock News
·
Jun 24

Everest Medicines Announces Mainland China Commercialization Deal with Hainan Herui for Budesonide Enteric Capsules

Bulletin Express
·
Jun 24